Background/Aims: Peritoneal protein loss (PPL) is associated with cardiovascular disease and mortality in peritoneal dialysis (PD). Controversial results have been published about the effect of paricalcitol in PPL among PD patients. This study intends to analyze the relationship between paricalcitol and PPL in PD. Methods: In a retrospective study, prevalent PD patients were divided into 2 groups: “with paricalcitol” and “without paricalcitol”. X2-test, Student’s t test, Pearson correlation coefficient and Logistic Regression analysis were applied. Results: Eighty-two patients were included. PPL was lower among patients medicated with paricalcitol (5.17 ± 1.71 vs. 6.79 ± 2.10 g/24 h, p = 0.0001). In multivariate analysis, paricalcitol and dialysate/plasma ratio of creatinine (D/P creatinine) were independently related to PPL (OR 4.270 [1.437–12.684], p = 0.009 and OR 0.205 [0.064–0.659], p = 0.008, respectively), adjusted for diabetes. Conclusion: Paricalcitol and D/P creatinine were independently related to PPL. Paricalcitol may have an effect on PPL in PD patients

Keywords:
Cardiovascular disease, Peritoneal membrane, Endotelial function, Peritoneal dialysis, Renin-angiotensin system, Vitamin D analogs
1.
Rubin J, Nolph KD, Arfania D, Prowant B, Fruto L, Brown P, Moore H: Protein losses in continuous ambulatory peritoneal dialysis. Nephron 1981; 28: 218–221.
2.
Cueto-Manzano AM, Gamba G, Correa-Rotter R: Quantification and characterization of protein loss in continuous ambulatory peritoneal dialysis. Rev Invest Clin 2000; 52: 611–617.
3.
Goffin E: Peritoneal membrane structural and functional changes during peritoneal dialysis. Semin Dial 2008; 21: 258–265.
4.
Sánchez-Villanueva R, Bajo A, Del Peso G, Fernandez-Reyes MJ, González E, Romero S, Estrada P, Selgas R: Higher daily peritoneal protein clearance when initiating peritoneal dialysis is independently associated with peripheral arterial disease (PAD): a possible new marker of systemic endothelial dysfunction? Nephrol Dial Transplant 2009; 24: 1009–1014.
5.
Perl J, Huckvale K, Chellar M, John B, Davies SJ: Peritoneal protein clearance and not peritoneal membrane transport status predicts survival in a contemporary cohort of peritoneal dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1201–1206.
6.
Szeto CC, Chow KM, Lam CW, Cheung R, Kwan BC, Chung KY, Leung CB, Li PK: Peritoneal albumin excretion is a strong predictor of cardiovascular events in peritoneal dialysis patients: a prospective cohort study. Perit Dial Int 2005; 25: 445–452
7.
Szeto CC, Chow KM, Chung KY, Kwan BC, Li PK: Peritoneal protein and albumin excretion as markers of cardiovascular risk factor and systemic endothelial dysfunction. Hong Kong J Nephrol 2004; 6: 31–37.
8.
Weir MR: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2: 581–590.
9.
Heaf JG, Sarac S, Afzal S: A high peritoneal large pore fluid flux causes hypoalbuminaemia and is a risk factor for death in peritoneal dialysis patients. Nephrol Dial Transplant 2005; 20: 2194–2201.
10.
Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM: Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis 2006; 47: 263–276.
11.
Helming L, Böse J, Ehrchen J, Schiebe S, Frahm T, Geffers R, Probst-Kepper M, Balling R, Lengeling A: 1alpha,25-Dihydroxyvitamin D3 is a potent suppressor of interferon gamma-mediated macrophage activation. Blood 2005; 106: 4351–4358.
12.
Mizobuchi M, Nakamura H, Tokumoto M, Finch J, Morrissey J, Liapis H, Slatopolsky E: Myocardial effects of VDR activators in renal failure. J Steroid Biochem Mol Biol 2010; 121: 188–192.
13.
Freundlich M, Quiroz Y, Zhang Z, Zhang Y, Bravo Y, Weisinger JR, Li YC, Rodriguez-Iturbe B: Suppression of renin-angiotensin gene expression in the kidney by paricalcitol. Kidney Int 2008; 74: 1394–1402.
14.
Agarwal R, Acharya M, Tian J, Hippensteel RL, Melnick JZ, Qiu P, Williams L, Batlle D: Antiproteinuric effect of oral paricalcitol in chronic kidney disease. Kidney Int 2005; 68: 2823–2828.
15.
Coronel F, Cigarrán S, Gomis A, Rodríguez-Cubillo B, Herrero JA, Delgado P, Delgado J: Changes in peritoneal membrane permeability and proteinuria in patients on peritoneal dialysis after treatment with paricalcitol – a preliminary study. Clin Nephrol 2012; 78: 93–99.
16.
Sánchez-Álvarez JE, Rodríguez-Suárez C, Coronel-Aguilar D, González-Díaz I, Núñez-Moral M, Peláez-Requejo B, Fernández-Viña A, Quintana-Fernández A: Paricalcitol reduces proteinuria but does not modify peritoneal protein loss in patients on peritoneal dialysis. Nefrologia 2013; 33: 70–76.
17.
Beddhu S, Bruns FJ, Saul M, Seddon P, Zeidel ML: A simple comorbidity scale predicts clinical outcomes and costs in dialysis patients. Am J Med 2000; 108: 609–613.
18.
Twardowski ZJ, Nolph KD, Khanna R, Prowant BF, Ryan LP, Moore HL, Nielsen MP: Peritoneal equilibration test. Perit Dial Int 1987; 7: 138–147.
19.
Williams JD, Craig KJ, Topley N, et al: Morphologic changes in the peritoneal membrane of patients with renal disease. J Am Soc Nephrol 2002; 13: 470–479.
20.
Nakamoto H, Imai H, Fukushima R, Ishida Y, Yamanouchi Y, Suzuki H: Role of the renin-angiotensin system in the pathogenesis of peritoneal fibrosis. Perit Dial Int 2008; 28(suppl 3):S83–S87.
21.
Duman S, Wieczorowska-Tobis K, Styszynski A, Kwiatkowska B, Breborowicz A, Oreopoulos DG: Intraperitoneal enalapril ameliorates morphologic changes induced by hypertonic peritoneal dialysis solutions in rat peritoneum. Adv Perit Dial 2004; 20: 31–36.
22.
Fishbane S, Chittineni H, Packman M, Dutka P, Ali N, Durie N: Oral paricalcitol in the treatment of patients with CKD and proteinuria: a randomized trial. Am J Kidney Dis 2009; 54: 647–652.
23.
Braun N, Fritz P, Biegger D, Kimmel M, Reimold F, Ulmer C, Alscher MD: Difference in the expression of hormone receptors and fibrotic markers in the human peritoneum – implications for therapeutic targets to prevent encapsulating peritoneal sclerosis. Perit Dial Int 2011;31: 291–300.
24.
González-Mateo GT, Fernández-Míllara V, Bellón T, Liappas G, Ruiz-Ortega M, López-Cabrera M, Selgas R, Aroeira LS: Paricalcitol reduces peritoneal fibrosis in mice through the activation of regulatory T cells and reduction in IL-17 production. PLoS One 2014; 9: 1–10.
25.
Wang T, Heimbürger O, Waniewski J, Bergström J, Lindholm B: Increased peritoneal permeability is associated with decreased fluid and small-solute removal and higher mortality in CAPD patients. Nephrol Dial Transplant 1998; 13: 1242–1249.
26.
Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D: Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int 2003; 63: 1483–1490.
27.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The collaborative study group. N Engl J Med 1993; 329: 1456–1462.
28.
Coronel F, Cigarrán S, García-Mena M, Herrero JA, Calvo N, Pérez-Flores I: Irbesartan in hypertensive non-diabetic advanced chronic kidney disease. Comparative study with ACEI. Nefrologia 2008; 28: 56–60.
29.
Nessim SJ, Perl J, Bargman JM: The renin-angiotensin-aldosterone system in peritoneal dialysis: is what is good for the kidney also good for the peritoneum? Kidney Int. 2010; 78: 23–28.
30.
Coronel F, Cigarrán S, Herrero JA, Delgado J, Ramos F, Gomis A: Peritoneal protein losses in diabetic patients starting peritoneal dialysis: is there a relationship with diabetic vascular lesions? Adv Perit Dial 2009; 25: 115–118.
31.
Nakamoto H, Imai H, Kawanishi H, Nakamoto M, Minakuchi J, Kumon S, Watanabe S, Shiohira Y, Ishii T, Kawahara T, Tsuzaki K, Suzuki H: Effect of diabetes on peritoneal function assessed by personal dialysis capacity test in patients undergoing CAPD. Am J Kidney Dis 2002; 40: 1045–1054.
32.
Honda K, Hamada C, Nakayama M, Miyazaki M, Sherif AM, Harada T, Hirano H: Impact of uremia, diabetes, and peritoneal dialysis itself on the pathogenesis of peritoneal sclerosis: a quantitative study of peritoneal membrane morphology. Clin J Am Soc Nephrol 2008; 3: 720–728.
33.
Schalkwijk CG, Poland DC, van Dijk W, Kok A, Emeis JJ, Drager AM, et al: Plasma concentration of C-reactive protein is increased in type I diabetic patients without clinical macroangiopathy and correlates with markers of endothelial dysfunction: evidence for chronic inflammation. Diabetologia 1999; 42: 351–357.
34.
de Zeeuw D, Agarwal R, Amdahl M, Audhya P, Coyne D, Garimella T, Parving HH, Pritchett Y, Remuzzi G, Ritz E, Andress D: Selective vitamin D receptor activation with paricalcitol for reduction of albuminuria in patients with type 2 diabetes (VITAL study): a randomised controlled trial. Lancet 2010; 376: 1543–1551.
35.
Chang TL, Kang EW, Lee YK, Shin SK: Higher peritoneal protein clearance as a risk factor for cardiovascular disease in peritoneal dialysis patient. PLoS One 2013; 8:e56223.
© 2018 S. Karger AG, Basel
2018
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.